IMMvention Therapeutix, Inc. Email Format
Biotechnology ResearchNorth Carolina, United States11-50 Employees
IMMvention Therapeutix, Inc. is a biotechnology research company focused on discovering and developing oral, first-in-class inhibitors of Bach1, a transcription factor, with the aim of creating transformative therapies for sickle cell disease and other chronic conditions such as renal, cardiometabolic, and neurodegenerative diseases. The work centers on delivering oral treatments that could be globally accessible to patients, emphasizing novel small molecule approaches in the therapeutic landscape. The company operates from Durham, North Carolina, and is positioned within the biotechnology research sector as a venture-funded enterprise pursuing innovative approaches to transcription factor–mediated disease pathways.